MEDITOPE BIOSCIENCES ENHANCES LEADERSHIP TEAM WITH NEW EXECUTIVE AND BOARD APPOINTMENTS
Pasadena, Calif., January 6, 2015 -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-drug conjugates (ADC) using its proprietary antibody technology platform, today announced two new leadership appointments: Robert Kramer, Ph.D., has joined the company's board of directors and Bob McKenzie, a current board member, has joined as Executive Vice President of Business Development.
"These two new appointments reflect our ongoing commitment to our strategy of advancing our own proprietary ADC programs, while leveraging our technology's relevance across a broad spectrum of applications," said Stephanie Hsieh, president and chief executive officer at Meditope. "Both Rob and Bob bring depth of experience and unique perspectives to our team that will be of immeasurable value as we pursue the many dimensions of this novel platform."
Dr. Kramer is an established pharmaceutical research executive with over 23 years of oncology drug discovery and development experience. Most recently, he was Global Head of Oncology Drug Discovery at Janssen (a Johnson & Johnson company). Prior to that, he was Vice President of Oncology and Immunology Drug Discovery at Bristol-Myers Squibb from 1995 to 2010, where he oversaw the company's Princeton, New Jersey research site, including more than 250 scientists and 40 preclinical programs. Several drug approvals resulted from discovery programs initiated under Dr. Kramer's leadership, including Sprycel® (dasatinib) for certain types of leukemia. He also championed immune oncology programs such as PD-1, an immune checkpoint agent that is a target for several new oncology drugs in development. Earlier in his career, Dr. Kramer served for five years as assistant professor in the Department of Radiation Therapy at Harvard Medical School, and he conducted his postdoctoral work at the National Institutes of Health. Dr. Kramer is an accomplished scientist and researcher who has successfully secured National Institutes of Health (NIH) funding and has over 40 peer-reviewed publications. He earned his Ph.D. in pharmacology at the University of Vermont and holds a B.S. in biology from SUNY at Stonybrook.
Bob McKenzie brings more than 25 years of experience in worldwide business development, as well as general and operational management expertise in sales and marketing, primarily in the technology industry. He was most recently vice president at Amdocs, a global leader in outsourced business services, where he oversaw key global accounts in the company's Broadband, Cable and Satellite division, and was responsible for strategic planning in the cable and satellite industry, product development, business development and program delivery. Mr. McKenzie is an internationally recognized business development professional, having orchestrated billion-dollar, transnational deals within the telecom and media industries. He earned his B.A. in Business Economics from the University of California at Santa Barbara and serves on the board of Stanford Youth Solutions.
About Meditope Biosciences, Inc.
Meditope Biosciences is a biotechnology company developing novel antibody-based cancer products using its SnAP technology (Site-specific novel Antibody Platform). Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, SnAP is capable of turning any antibody into a proprietary, site-specific "Lego-like" system that is able to attach and detach nearly anything to an antibody without the need for chemical conjugation. Meditope's SnAP technology has the potential to advance the antibody market by producing an array of new therapeutic and diagnostic products. More information can be found by visiting www.meditope.com.